Congratulations to our client 4D Molecular Therapeutics for appointing Kristian F. Humer as Chief Financial Officer.
4DMT is a leading late-stage biotechnology company developing durable, disease-targeted therapeutics with the potential to transform treatment paradigms and deliver unprecedented patient benefits. Its lead product candidate, 4D-150, is designed as a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) through a single intravitreal injection, significantly reducing the treatment burden of current bolus injections. The lead indication for 4D-150 is wet age-related macular degeneration, now in Phase 3, with diabetic macular edema as a second indication. The Company’s second product candidate, 4D-710, is the first known genetic medicine to achieve successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
C1 Team: Christos Richards & Leo Cain